. Author manuscript; available in PMC: 2017 Aug 23.

Published in final edited form as: Nat Rev Cancer. 2016 Aug 23;16(9):566–581. doi: 10.1038/nrc.2016.97

Table 2.

Examples of engineered TCR clinical trials (clinicaltrials.gov)

Target	Indication	Reference
MAGEA3	Various solid tumors	NCT02153905
MAGEA3	Various solid tumors	NCT02111850, ¹⁸⁰
MAGEA4	Various solid tumors	NCT02096614
NY-ESO1 +/−LAGE-1 +/− MAGE3/6	Various solid tumors	NCT02366546
		NCT02457650
		NCT02070406
		NCT00670748, ^8,181
	Various malignancies	NCT01697527
	Melanoma	NCT01350401
	Metastatic non-melanoma	NCT01967823
	Mesothelioma, NSCLC	NCT02408016
	Multiple myeloma	NCT01892293
	Multiple myeloma	NCT01352286, ⁷
WT1	Myeloid malignancy	NCT01621724
		NCT02550535
		NCT01640301
MART1	Metastatic melanoma	NCT02654821
MART1	Metastatic melanoma	NCT00910650, ¹⁸²
HPV16-E6	HPV associated cancers	NCT02280811
Thyroglobulin	Metastatic thyroid cancer	NCT02390739
Melanoma antigen tyrosinase	Melanoma	NCT01586403
CEA	Various solid tumor	NCT01723306